Last reviewed · How we verify
GPO ritonavir versus Norvir
At a glance
| Generic name | GPO ritonavir versus Norvir |
|---|---|
| Sponsor | The HIV Netherlands Australia Thailand Research Collaboration |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Pharmacokinetics and Safety of Rifabutin 150 mg Once Daily Versus Rifabutin 300 mg Thrice Weekly (PHASE2)
- Bioequivalence Study of Generic GPO Saquinavir and Norvir® Versus Invirase® and Norvir® (PHASE1, PHASE2)
- Bioequivalence Study of Generic GPO Ritonavir Versus Norvir® (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: